Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants
Year: 2024
Type: article
Abstract: Background: SARS-CoV-2 Omicron lineage contains variants with multiple sequence mutations relative to the ancestral strain particularly in the viral spike gene. These mutations are associated inter alia with loss of neutralization sensitivity to sera generated by immunization with vaccines targeting ancestral strains or prior infection with circulating (non-Omicron) variants. Here we present a comparison of vaccine formulation elicited cross neutralization responses using two different assay readouts from a subpopulation of a Phase II/III clinical trial. Methods: Human sera from a Phase II/III trial (NCT04762680) was collected and evaluated for neutralizing responses to SARS-CoV-2 spike antigen protein vaccines formulated with AS03 adjuvant, following a primary series of two-doses of ancestral strain vaccine in individuals who were previously unvaccinated or as an ancestral or variant strain booster vaccine among individuals previously vaccinated with the mRNA BNT162b2 vaccine. Results: We report that a neutralizing response to Omicron BA.1 is induced by the two-dose primary series in 89% of SARS-CoV-2-seronegative individuals. A booster dose of each vaccine formulation raises neutralizing antibody titers that effectively neutralizes Omicron BA.1 and BA.4/5 variants. Responses are highest after the monovalent Beta variant booster and similar in magnitude to human convalescent plasma titers. Conclusion: The findings of this study suggest the possibility to generate greater breadth of cross-neutralization to more recently emerging viral variants through use of a diverged spike vaccine in the form of a Beta variant booster vaccine.
Source: Heliyon
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,100
Funders: Vejchewin Research Institute, U.S. Department of Defense, U.S. Department of Health and Human Services, GlaxoSmithKline, Sanofi, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Institut Pasteur, Swiss Vaccine Research Institute, Biomedical Advanced Research and Development Authority
Awards: G1180553477, G1329347818, G1597571876, G1724543635, G1979782309, G282427092, Consequences of SARS-CoV-2 infection on cellular and mitochondrial functions, G5172521765, Initiative for the creation of a Vaccine Research Institute, G7240651115, Integrative Biology of Emerging Infectious Diseases, G7524130973, G8670608220
OpenAlex ID: W4392246939
